Advertisement

Topics

PCI Biotech: Publication of the fimaporfin (Amphinex) first-in-man Phase I study in Lancet Oncology

04:31 EDT 28 Jul 2016 | GlobalNewsWire (2014)

This article has expired, however you can still download the PDF.
Preview:
Oslo, 28 July 2016 - PCI Biotech (PCIB) a cancer focused Norwegian biopharmaceutical company, reported today that the first-in-man Phase I study with PCI Biotech's proprietary drug fimaporfin (AmphinexTM) performed at University College ...

Other Sources for this Article

NEXT ARTICLE

More From BioPortfolio on "PCI Biotech: Publication of the fimaporfin (Amphinex) first-in-man Phase I study in Lancet Oncology"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...